Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks

Julián Olalla1*, Javier Pérez-Stachowski1, Begoña Tortajada2, Alfonso Del Arco1, Efrén Márquez2, Javier De la Torre1, Miriam Nieto2, José María García de Lomas1, José Luis Prada1 and Javier García-Alegría1

https://doi.org/10.1186/s40360-018-0252-z

The original publication of this article did not provide clear clarification that the switch from brand to a generic drug was not done by the authors for the intention of the study. Patients were informed of the options and on switching to generic drugs the patients were able to express their agreements or disagreements, those who expressed their disagreement continued with their regimen.

Published online: 06 October 2023

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.